Impact Biomedical
Biotechnology company focused on discovery, patenting, and partner-driven development of health and wellness technologies spanning biopharmaceutical R&D and consumer wellness products. Core activities include formulation platforms based on polyphenols, botanical formulations, low-glycemic sugar compositions, acquisition and development of air-purification systems, and strategic partnerships for development, licensing and commercialization.
Industries
Nr. of Employees
small (1-50)
Impact Biomedical
Products
Polyphenol-based formulation platform for therapeutics
Platform designed to modify therapeutic compounds using X-bonded polyphenols to improve pharmacological properties for oncology, neurology and inflammatory indications.
Low-glycemic sugar composition
Formulation combining sugars with myo-inositol intended to reduce glycemic response and inflammatory signaling for dietary and potential therapeutic applications.
Botanical insect-repellent and antimicrobial formulations
Natural-fragrance-based formulations intended for insect repellent and antimicrobial uses, and as additives for detergents, lotions, fabrics and personal care.
Portable air-purification systems with patented filtration
Portable air filtration systems designed to provide near clean-room air quality using patented filter designs and methods; positioned for indoor air-quality applications.
Equivir
A novel FDA Generally Recognized as Safe (GRAS) eligible polyphenol blend with proven antiviral effects and potential applications as medication or supplements.
Equivir-G
Adds gallic acid to the Equivir composition, resulting in a unique formulation with demonstrated antiviral effects.
Polyphenol-based formulation platform for therapeutics
Platform designed to modify therapeutic compounds using X-bonded polyphenols to improve pharmacological properties for oncology, neurology and inflammatory indications.
Low-glycemic sugar composition
Formulation combining sugars with myo-inositol intended to reduce glycemic response and inflammatory signaling for dietary and potential therapeutic applications.
Botanical insect-repellent and antimicrobial formulations
Natural-fragrance-based formulations intended for insect repellent and antimicrobial uses, and as additives for detergents, lotions, fabrics and personal care.
Portable air-purification systems with patented filtration
Portable air filtration systems designed to provide near clean-room air quality using patented filter designs and methods; positioned for indoor air-quality applications.
Equivir
A novel FDA Generally Recognized as Safe (GRAS) eligible polyphenol blend with proven antiviral effects and potential applications as medication or supplements.
Equivir-G
Adds gallic acid to the Equivir composition, resulting in a unique formulation with demonstrated antiviral effects.
Services
Out-licensing and co-development partnerships for platform technologies across biopharmaceutical and consumer wellness markets.
Immediate availability for partnering and out-licensing of consumer-facing formulations such as low-glycemic sugar compositions and botanical repellents/antimicrobials.
Out-licensing and co-development partnerships for platform technologies across biopharmaceutical and consumer wellness markets.
Immediate availability for partnering and out-licensing of consumer-facing formulations such as low-glycemic sugar compositions and botanical repellents/antimicrobials.
Expertise Areas
- Biopharmaceutical discovery and preclinical development
- Nutraceutical and consumer-wellness product formulation
- Antiviral and antimicrobial product development
- Formulation chemistry for improved bioavailability
Key Technologies
- Polyphenol-based formulation platforms
- Sugar–myo-inositol low-glycemic compositions
- Botanical terpene formulations
- Antiviral and antimicrobial efficacy assays
News & Updates
Announcement of a merger and share exchange agreement to combine with Dr Ashleys Limited, subject to shareholder and regulatory approvals; transaction intended to form a new NYSE American-listed PubCo.
Announcement of acquisition of an air purification technology company in an all-equity transaction; acquisition includes patented filter designs and U.S. manufactured portable systems.
Press release stating there was no material development to account for unusual market activity regarding the company's share price.
Announcement that the CEO will present company developments and strategy at The Microcap Conference 2025.
U.S. Patent No. 11,898,184 issued for a low-glycemic sugar composition combining sugars and myo-inositol; patent term stated to expire in 2037.
Company completed an initial public offering in September 2024 and listed on the NYSE American under the ticker IBO.
Announcement of a merger and share exchange agreement to combine with Dr Ashleys Limited, subject to shareholder and regulatory approvals; transaction intended to form a new NYSE American-listed PubCo.
Announcement of acquisition of an air purification technology company in an all-equity transaction; acquisition includes patented filter designs and U.S. manufactured portable systems.
Press release stating there was no material development to account for unusual market activity regarding the company's share price.
Announcement that the CEO will present company developments and strategy at The Microcap Conference 2025.
U.S. Patent No. 11,898,184 issued for a low-glycemic sugar composition combining sugars and myo-inositol; patent term stated to expire in 2037.
Company completed an initial public offering in September 2024 and listed on the NYSE American under the ticker IBO.